<DOC>
	<DOC>NCT02117258</DOC>
	<brief_summary>The primary objective of this study is to compare the efficacy of GEM plus Z-360 versus GEM plus placebo on the overall survival (OS) in subjects with metastatic Pancreatic Adenocarcinoma.</brief_summary>
	<brief_title>Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1. Subjects with histological or cytological evidence of metastatic Pancreatic Adenocarcinoma, Measurable disease or nonmeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version criteria 2. Subjects with a life expectancy of at least 12 weeks, 3. Subjects with an Eastern cooperative oncology group performance status (ECOG PS) of 0, 1 or 2, 4. Subjects with the following adequate organ functions: White blood cell count ≥3,000/μL (or absolute neutrophil count ≥1,500/μL) and ≤ 12,000/μL , Platelet count ≥100.0 × 10^9/L, Hemoglobin ≥9.0 g/dL, Serum creatinine ≤1.5 × the upper limit normal (ULN), Total bilirubin ≤2.0 × ULN, Serum aspartate transaminase levels ≤3.0 × ULN (≤5.0 × ULN in presence of liver metastases), and Serum alanine aminotransferase levels ≤3.0 × ULN (≤5.0 × ULN in presence of liver metastases). Subjects received the following previous therapies for Pancreatic Adenocarcinoma: Surgery within the 4 weeks prior to randomization, Radiation and chemoradiation within the 12 weeks prior to randomization, Radiation for pain relief within the 4 weeks prior to randomization, Gemcitabine used as a neoadjuvant or an adjuvant on surgery within the 24 weeks prior to randomization, Chemotherapy except GEM used as an adjuvant on surgery within the 4 weeks prior to randomization, Gemcitabine ≥600 mg/m^2 as sensitizer for chemoradiation, Gemcitabine &lt;600 mg/m^2 as sensitizer for chemoradiation within the 12 weeks prior to randomization, Gemcitabine used for systemic chemotherapy, or Systemic chemotherapies except GEM within the 4 weeks prior to randomization.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Z-360, Pancreatic cancer, Pancreatic Adenocarcinoma</keyword>
</DOC>